CSI Market
Sign In | Register

Aclaris Therapeutics Inc (ACRS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ACRS Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Aclaris Therapeutics Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-41.33
Depreciation & amortization0.21
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.30
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation5.87
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
In Process Research And Development Expense-
Increase Decrease In Contract With Customer Liability-0.85
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable2.36
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-3.10
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.30
Discontinued operations0.00
Net Cash flow from Operating Activities-38.00
Investing Activities
Capital Expenditures-0.07
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities40.00
Payments to Acquire Marketable Securities-60.60
Real Estate Investments0.00
Payments To Acquire Product Under Collaborative Arrangement-
Receipts From Disposition Of Product Under Collaborative Arrangement-
Payment Of Deferred Transactions Consideration To Acquire Intangible Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-57.88
Discontinued operations0.00
Net Cash Flow from Investing Activities-20.67
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.27
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.27
Other net57.88
Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs-
Proceeds From Issuance Of Private Placement Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Issuance Initial Public Offering Net Of Issuance Costs-
Payment Of Development Milestone Financing-
Finance Lease Principal Payments-
Sale Of Stock Consideration Received On Transaction57.88
Capital Expenditures Incurred But Not Yet Paid0.06
Fair Value Of Warrants Issued In Connection With Debt Financing-
Operating Lease Asset Recorded As Result Of New Accounting Standard-
Stock Issued-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities57.87
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-38.07
Total Cash Flow-0.79
4 historic quarters locked

Sign in to unlock the full Aclaris Therapeutics Inc cash flow history.

Sign In Create Free Account

About Aclaris Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-092065

Figures are derived from filed reports and may be restated. Historical data is subject to revision.